As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

Pfizer CEO Albert Bourla has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing that his ...

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers ...

Pfizer (PFE) and other drugmakers met with the Trump administration to discuss lowering U.S. drug prices but no commitments have been made, Pfizer CEO Albert Bourla said on Monday at the Goldman Sachs ...

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

(Reuters) -Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

Despite an outcry from the biopharmaceutical industry, the U.K. government has kept the rebate rate under a national ...

Pfizer and other drug companies have met with the Trump administration to discuss most-favored-nation pricing but no commitments have been made, Chief Executive Albert Bourla said on Monday at an ...

CEO Albert Bourla has reportedly said that the company has made no commitments during its meeting with the Trump ...

BioSpace did a deep dive into executive pay, examining the highest compensation packages, pay ratios and golden ...

Americas Society recognized Venezuela's opposition leader and two business executives with the Gold Medal for their impact on ...

Pfizer offers a dividend yield over 7%, but it's payout probably won't rise very fast in the decade ahead. Investors seeking ...